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This review is intended to evaluate the research findings and potential clinical
applications of drug transport systems, developed based on the concepts of the
structure/function and physiological role(s) of high density lipoprotein type nanoparticles.
These macromolecules provide targeted transport of cholesteryl esters (a highly lipophilic
payload) in their natural/physiological environment. The ability to accommodate highly
water insoluble constituents in their core regions enables High density lipoproteins (HDL)
type nanoparticles to effectively transport hydrophobic drugs subsequent to systemic
administration. Even though the application of reconstituted HDL in the treatment of a
number of diseases is reviewed, the primary focus is on the application of HDL type
drug delivery agents in cancer chemotherapy. The use of both native and synthetic
HDL as drug delivery agents is compared to evaluate their respective potentials for
commercial and clinical development. The current status and future perspectives for HDL
type nanoparticles are discussed, including current obstacles and future applications in
therapeutics.
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HDL AS A TRANSPORT VEHICLE
High density lipoproteins (HDL) participate in reverse cholesterol transport in mammals to deliver
the peripherally accumulated excess cholesterol to the liver (Rader et al., 2009). The structure ofHDL
is superbly suited for the transport of cholesteryl esters and lipophilic compounds, including drugs
(Figure 1) in its core compartment so that the cholesterol payload can safely reach its destination
(Lund-Katz and Phillips, 2010). The same advantages apply to the transport of other lipophilic
payloads, including drugs that can be delivered to specific cell/tissue targets via HDL type carriers
(Lacko et al., 2002, 2007; Sabnis and Lacko, 2012). Despite the growing interest in HDL as a drug
delivery/therapeutic agent (Ng et al., 2011; Huang et al., 2015; McMahon et al., 2015), clinical
studies have yet to be initiated with this transport vehicle. While recent literature reports in this
area suggest a marked upsurge in research activity that rely on reconstituted HDL (rHDL) type
nanoparticles, major review articles and books often ignore lipoprotein based drug delivery, in
favor of sophisticatedly engineered and often more complex and potentially much more expensive
nanoparticles. For example, a recent multi-volume treatise on “Nanobiomedical Research” contains
no information on lipoprotein based drug delivery whatsoever. Perhaps a breakthrough finding
regarding enhanced therapeutic potential of drugs will provide the momentum for the development
of HDL type therapeutic transport vehicles.
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FIGURE 1 | Localization of a hydrophobic drug (paclitaxel) in the core region of synthetic (reconstituted) HDL (rHDL). Adapted from Weinberg (1987).
HDL AS A DRUG DELIVERY VEHICLE
The use of lipoproteins and particularly HDL (Schouten et al.,
1993) as drug delivery agents was first suggested over 30 years
ago (Counsell and Pohland, 1982). Subsequently, Kader and
Pater (2002) evaluated HDL particles as drug transporters. They
have found that drugs incorporated into HDL were 2.5–23
times cytotoxic to cancer cells than the free (non-encapsulated)
drug. Despite these promising findings, the use of plasma
lipoproteins as drug carriers has been limited by the lack of
their consistent composition (depending on the source) and the
potential for harboring infectious agents. Since then significant
research activity followed in this area using synthetic/rHDL
nanoparticles (Lacko et al., 2007; Ng et al., 2011; Huang et al.,
2015; McMahon et al., 2015). The slow development of HDL type
drug formulations toward clinical applications is surprising as
these nanoparticles have numerous advantageous characteristics,
including:
(1) Enhanced safety and efficacy yielding a sturdy, non-leaking
preparation due to a structure stabilized by apolipoproteins,
particularly apolipoprotein A-I (apo A-I).
(2) Biocompatibility and safety, shown by several
pharmaceutical formulations, made up of essentially
the same ingredients as rHDL (Kujiraoka et al., 2003;
Hovingh et al., 2015; Kootte et al., 2015).
(3) The receptor-mediated uptake of the payload, carried in the
core of the HDL particle (Figure 1) makes this strategy
uniquely applicable, especially for cancer chemotherapy
(Lacko et al., 2007; Ng et al., 2011).
SYNTHETIC/RECONSTITUTED HDL AS
A DRUG DELIVERY VEHICLE
Because of the concerns about infectious agents and the
reproducibility of samples of human plasma HDL, its use for drug
delivery in a clinical setting seems impractical. Consequently,
most of the research activity in the last 20 years has focused
on the development and evaluation of rHDL drug delivery
vehicles (Table 1). In a previous review (Lacko et al., 2007),
we discussed the physical chemical characteristics of the rHDL
drug delivery particles, especially regarding the discrepancy
in the preparatory procedures and the shape and size of the
resultant particles. Since then, there has been an effort to
identify discoidal particles as “nanodisks” (Tufteland et al.,
2008) or discoidal particles to differentiate them from spherical
structures (Wang et al., 2013). The latter rHDL particles have
been assembled using a variety of methods. Including sonication
(Zhang et al., 2009) and detergent dialysis (McConathy et al.,
2008) producing largely spherical, HDL like nanoparticles. The
distinction between the discoidal and spherical rHDL particles is
likely to be physiologically and pharmacologically significant as
their respective drug carrying capacities andmetabolism are likely
to be different.
APO A-I MIMETIC PEPTIDES AS
COMPONENTS OF HDL TYPE DRUG
DELIVERY VEHICLES
Commercial development of HDL drug delivery vehicles has been
hampered, at least to a degree, by the availability of the protein
component apo A-I (Ryan et al., 2003). Sufficient quantities of
human apo A-I for scaling up and eventual industrial production
are currently not commercially available.
Alternatives to apo A-I or other full length apolipoproteinsmay
be appropriately found via the application of mimetic peptides
(Remaley et al., 2003) in the assembly of rHDL nanoparticles
(Zhang et al., 2010). These peptides are designed to contain
amphipathic helical structures, similar to the helical bundles
that have been identified in apo A-I (Ditiatkovski et al., 2013;
Leman et al., 2014). The apo A-I mimetic peptides thus, for
the most part, mimic the function of apo A-I by contributing
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TABLE 1 | Landmarks in the development of HDL type nanoparticles for
the delivery of drugs and nucleic acids.
Findings and conclusions Reference
Proposed lipoproteins as vehicles for site-specific
delivery of radiopharmaceuticals.
Counsell and Pohland (1982)
Lactosylated apo E containing (synthetic)
neo-HDL is rapidly taken up by parenchymal liver
cells.
Schouten et al. (1993)
Loading anticancer drugs into HDL or LDL
enhances their cytotoxicity toward cancer cells.
Kader and Pater (2002)
Reconstituted HDL can effectively deliver drugs to
cancer cells due to their over expression of the
SR-B1 receptor.
Lacko et al. (2002)
rHDL-paclitaxel nanoparticles had superior
cytotoxicity against prostate, breast and ovarian
cancer cells (compared to the free drug) and were
better tolerated by mice than either Taxol or
Abraxane.
McConathy et al. (2008)
rHDL nanoparticles utilized for cytosolic delivery of
drugs.
Zhang et al. (2009)
Assembly of gold containing rHDL nanoparticles
for drug delivery.
Thaxton et al. (2009)
rHDL nanoparticles containing apo A-I mimetic
peptide for drug delivery to malignant tumors.
Zhang et al. (2010)
The SR-B1 receptor is primarily (82%) responsible
of for the uptake of paclitaxel from rHDL
nanoparticles by prostate cancer (PC-3) cells.
Mooberry et al. (2010)
rHDL delivered STAT3 siRNA contributed to 90%
suppression of ovarian tumor xenografts while
inducing a fivefold increase in apoptosis and a
threefold decrease in tumor angiogenesis. Tumor
uptake of the siRNA form rHDL appeared to be
facilitated by the SR-B1 receptor.
Shahzad et al. (2011)
Improved therapeutic efficacy of anti-cancer
agents via encapsulation into rHDL nanoparticles.
Sabnis et al. (2012, 2013)
rHDL particles can be prepared via a
microfluidizer.
Kim et al. (2013)
Super paramagnetic iron oxide can be
encapsulated into rHDL nanoparticles along with
drugs and directed toward their target in a
magnetic field.
Sabnis et al. (2015)
to lipoprotein assembly (Zhang et al., 2010) and receptor
interactions. Interestingly, the apolipoprotein component of
HDL/rHDL (apo A-I) has been found to have anti-tumor effect
on its own (Zamanian-Daryoush et al., 2013), perhaps due to
its anti-inflammatory impact (Gomaraschi et al., 2008) or via an
alternative mechanism modulating innate immunity (Zamanian-
Daryoush et al., 2013). This is an intriguing property of HDL
and rHDL nanoparticles that has also been observed with apo
A-I mimetics as well (Su et al., 2012). This feature and other
favorable characteristics may eventually allow the use of apo A-I
mimetics to replace the full-length protein in rHDL nanoparticle
formulations.
RECONSTITUTED LIPOPROTEINS
AND rHDL VS LIPOSOMES
Because liposomes are the most widely used drug delivery
vehicles, especially for cancer chemotherapy, it is worthwhile to
compare their performance with lipoprotein based drug delivery
vehicles in general and with rHDL in particular. Liposomes are
spherical lipid based bilayers, generally with a diameter in the
100–200 nm range, with the capacity to improve the delivery and
therapeutic efficacy of intravenous drug formulations (Bozzuto
andMolinari, 2015). Lipoproteins, especially HDL, appear to have
two major advantages over liposomes as drug delivery agents.
First, lipoproteins, including, synthetic lipoprotein formulations,
tend to be much smaller (10–50 nm diameter) than liposomes.
These feature maybe a significant advantage as the drug carrying
nanoparticles are designed with the aim of effectively penetrating
the tumor environment. Secondly, both LDL and HDL interact
with cell surface receptors via their surface components and
thus may have the capacity to reach selective cellular targets
depending on the expression levels of specific receptors (see next
section). Liposomes, on the other hand, need to be conjugated
with antibodies or other targeting moieties that in all likelihood
complicate the assembly process and also results in extended costs
of preparation.
RECEPTOR MEDIATED DRUG DELIVERY
VIA HDL TYPE NANOPARTICLES
The natural payload of circulating HDL particles, cholesteryl
esters, are known to be primarily delivered via a specific
mechanism (selective delivery) using the scavenger receptor type
B1 (SR-B1) receptor (Steinberg, 1996; Connelly and Williams,
2004). This mechanism has been linked to a fortuitous finding of
SR-B1 overexpression in cancer cells when compared to normal
cells (Lacko et al., 2002). Since then several other studies have
confirmed that most malignant cells and tumors overexpress this
receptor (Zhang et al., 2009; Mooberry et al., 2010; Shahzad
et al., 2011; Yang et al., 2013; Ding et al., 2014), perhaps to
meet their need for cholesterol, demanded by their high rate
of proliferation (Cruz et al., 2013). These findings led us to
propose an rHDL drug delivery hypothesis (Lacko et al., 2006)
that allows the selective delivery of anti-cancer agents to cancer
cells and tumors via the SR-B1 receptor thus unloading of the
drug payload from rHDL nanoparticles to cancer cells. This
mechanism could allow a “Trojan Horse” strategy (Lacko et al.,
2006) that may be particularly effective against cancer cells and
tumors.
HDL TYPE NANOPARTICLES AS
DRUG CARRIERS FOR CANCER
CHEMOTHERAPY
Reconstituted HDL type nanoparticles have been extensively
studied as drug delivery agents for the purpose of developing
enhanced chemotherapy strategies (McConathy et al., 2008;
Zhang et al., 2010; Shahzad et al., 2011; Ditiatkovski et al.,
2013; Yang et al., 2013). Combined with the receptor mediated
drug delivery concept, rHDL nanoparticles may have broad
applicability in therapeutics, especially for cancer therapy because
during pre-clinical studies, normal cells, for the most part,
were found to be shielded from the toxic effect of drugs,
opening the way for designing novel chemotherapy regimens
via rHDL with much reduced side effect (Sabnis et al., 2012,
2013).
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The overexpression of the SR-B1 receptor by most cancer cells
and tumors (Lacko et al., 2002; Zhang et al., 2009; Mooberry
et al., 2010; Shahzad et al., 2011; Yang et al., 2013; Ding et al.,
2014) appears to be a key feature of malignant transformation and
development (Cruz et al., 2013). It is a nearly universal feature of
malignant cells and tissues, a biological group that is known for
its extreme heterogeneity. Consequently, the overexpression of the
SR-B1 receptor bymalignant cells and tissuesmay be of significant
value in cancer therapeutics.
1. As mentioned above, tumor specific delivery of anti-cancer
agents may be possible while protecting normal tissues and
thus avoiding side effects.
2. This approach may also be applicable to personalized (or
precision) therapy where tumor biopsy samples may be
assessed for their SR-B1 expression to select those patients
that are most likely to be responsive to therapy.
3. The tumor selective drug delivery concept may have
particular relevance to pediatric cancer therapy (Sabnis et al.,
2015a; Sabnis et al., 2015) where the immediate and delayed
side effects of drug treatment induce particularly severe
consequences.
HDL AS A DRUG CARRIER FOR TREATING
CARDIOVASCULAR DISEASE
There have been only a handful of reports describing the potential
use of rHDL nanoparticles for the treatment of cardiovascular
disease. These include Tanshinone IIA loaded reconstituted
high density lipoproteins (TA-rHDL) for atherosclerotic plaque
targeting mechanism in a foam cell model (Zhang et al., 2012).
The pharmacokinetic studies in rabbits have shown that TA-rHDL
was a long-circulating, safe and potentially targeted carrier for
delivering lipophilic cardiovascular drugs (Vickers et al., 2011).
They also showed that cholesterol homeostasis is coordinated by
microRNA 223 via post transcriptional control of multiple genes
in lipoprotein and cholesterol metabolism.
Vickers et al., 2011 showed that HDL transports endogenous
miRNAs and delivers them to recipient cells with functional
targeting capabilities. rHDL injected into mice retrieved distinct
miRNA profiles from normal and atherogenic models (Vickers
et al., 2011). HDL delivery of both exogenous and endogenous
miRNAs resulted in the direct targeting of messenger RNA
reporters. HDL-miRNA from atherosclerotic subjects induced
differential gene expression, with significant loss of conserved
mRNA targets in cultured hepatocytes. The potential for rHDL in
cardiovascular therapeutics via the payload being delivered to the
endothelial surface is a rapidly growing and potentially effective
area for treating atherosclerosis and related abnormalities.
NUCLEIC ACID DELIVERY VIA HDL TYPE
NANOPARTICLES
Nucleic acids, including anti-sense nucleotides, siRNA and
non-coding RNAs have been used extensively to modulate
gene expression and more recently have been considered for
therapeutic applications (Bali and Kuner, 2014; Farooqi et al.,
2014; Kaur et al., 2014). Although these nucleic acids may be
utilized as therapeutic agents, certain major issues limit their
utility for clinical applications. These include their sensitivity
toward serum nucleases which markedly reduces their serum
half-life (Yin et al., 2014), their anionic surface charges that
prevent them from penetrating the cell membrane, and their
immune-stimulatory potential that triggers the immune response
(Dobrovolskaia and McNeil, 2015). Additionally, low therapeutic
efficiency of nucleic acids has also been reported due to their non-
specific bio-distribution and subsequent off target effects (Zhu
and Mahato, 2010).
Subsequently, extensive research on several delivery strategies
has led to the design of novel transport systems that are likely to
overcomemost, if not all, of these barriers to effective nucleic acid
therapeutics (Lovell et al., 2011; Shahzad et al., 2011; Yang et al.,
2011; Jin et al., 2012; Ding et al., 2014; Pensado et al., 2014; Pandey
and Kanduri, 2015). Earlier, Bijsterbosch et al. (2000) showed that
cholesterol-nucleic acid conjugates facilitated the accumulation of
phosphorothioate oligo-deoxynucleotides (ODN) in liver cells to
achieve anti-sense therapy of liver disease. Wolfrum et al. (2007)
showed that after systemic administration the lipid-conjugated
siRNAs are capable of inducing the silencing of specific genes in
the liver.
Vickers et al. (2011) showed that HDL transports endogenous
miRNAs and delivers them to recipient cells with functional
targeting capabilities. Furthermore, rHDL injected into mice
was observed to retrieve distinct miRNA profiles from normal
and atherogenic models. HDL delivery of both exogenous
and endogenous miRNAs resulted in the targeting of specific
messenger RNA reporters. HDL-miRNA complexes from
atherosclerotic subjects induced differential gene expression,
with significant loss of conserved mRNA targets in cultured
hepatocytes. Overall, these observations indicate that HDL
participates in a mechanism of intercellular communication
involving the transport and delivery of miRNAs to and from cells
that express SR-B1 receptor (Vickers et al., 2011). Furthermore,
these findings suggest that rHDL is likely to be an efficient carrier
for the targeted delivery of miRNA and other low molecular
weight polynucleotides for therapeutic purposes.
Accordingly, the delivery of siRNA via lipoprotein carriers
has been studied extensively (Lovell et al., 2011; Shahzad et al.,
2011; Yang et al., 2011; Jin et al., 2012; Ding et al., 2014) while
considerably less information is available on miRNA delivery
(Vickers and Remaley, 2012).
An HDL-mimicking peptide-phospholipid nanoscaffold
(HPPS) for siRNA delivery has been developed by Yang et al.
(2011) with the unique capability of cytosolic delivery of
cholesterol-conjugated siRNA. The mechanism of siRNA delivery
via these nanoparticles involves the bypass of endolysosomal
trafficking and selective delivery of the RNAi to targeted
subcellular compartments. In another study, McMahon et al.,
2015 described a gold nanoparticle-templated HDL platform
(HDL AuNP) for gene therapy. This strategy combines lipid-
based nucleic acid delivery that mimics the function of HDL
(Vickers et al., 2011). These HDL AuNPs have also been shown to
adsorb anti-sense cholesterol-conjugated DNA with subsequent
internalization of these conjugates by human cells.
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CONCLUSION
The concept of delivering therapeutic agents via HDL type
transport vehicles has come a long way since the original
postulates of Counsell and Pohland (1982) as the receptor
mediated uptake of drugs and the extended safe circulation
time are attractive features of these nanoparticles. The rHDL
drug deliverymodel may have particularly important applications
in cancer therapeutics because of the potential for tumor
selective delivery of anti-cancer agents (Shahzad et al., 2011).
Strengthening the pre-clinical proof of concept will likely pave the
way for clinical trials and ultimately the therapeutic application of
the rHDL nanoparticles.
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